Global Peptide Therapeutics Market Trends, Forecast Report 2025-2037
Peptide Therapeutics Market size was over USD 46.83 billion in 2024 and is anticipated to cross USD 103.62 billion by 2037, witnessing more than 6.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of peptide therapeutics is assessed at USD 49.49 billion.
The increasing prevalence of chronic diseases is inflating the demand in this sector. According to a report published by WHO in September 2023, cardiovascular diseases cause 17.9 million NCD deaths annually. The report further states that more death cases accounted for 9.3 million by cancer, 4.1 million by respiratory diseases, and 2 million by diabetes.
The growing volume of the global aging population has also propelled the incidence rates of such chronic diseases. Thus, the healthcare industry is seeking innovative treatment methods to address the unmet medical needs of these conditions. The peptide therapeutics market has introduced the most effective solutions to treat or prevent these life-threatening conditions. Many companies are now focused on developing new formulations to offer better patient outcomes. For instance, in June 2023, Evonik launched a new performance-boosting peptide, cQrex KC for manufacturing new biological drugs. The new addition increases the productivity of cell culture to produce monoclonal antibodies, vaccines, viral vectors, and cell therapies.
Peptide Therapeutics Sector: Growth Drivers and Challenges
Growth Drivers
- Extensive R&D in this sector: With the advancement in biotechnology and drug development, innovations have been impelled in the peptide therapeutics market. Significant investments and efforts have been made to discover novel peptide drugs. Many biotech companies and pharmaceutical companies are conjugately fueling R&D in this industry to expand their therapeutic pipeline. In July 2021, Lilly acquired Protomer Technologies in a transaction of USD 1.0 billion to excel in its future R&D on peptide and protein drugs. With this acquisition, the company will utilize Protomer’s peptide- and protein-engineering platform that can sense molecular activators in the body to develop glucose-sensing insulin for diabetes.
- Development in precision and targeted healthcare: The peptide therapeutics market is greatly contributing to the development of personalized medicines. With recent discoveries, it has been evident that peptides can serve as an excellent precise agent for cancer immunotherapies and biomarkers. This has further inflated the need for more innovative peptide drugs. According to a study conducted by NLM in October 2021, peptides with improved delivery systems and increased bioavailability can be a revolutionary therapeutic for cancer treatment. Innovative delivery systems such as liposomal formulations, nanoparticles, and oral delivery technologies can utilize the high target specificity and low toxicity for cancer cell death.
Challenges
- Market accessibility and pricing issues: Being more expensive than the other small-molecule components can reduce the demand in the peptide therapeutics market of cost-sensitive regions. Its complex production and formulation process often creates hurdles in setting pricing strategies. Producing peptides with high purity at a large can be challenging as methods such as SPPS or liquid phase can be costly. This may further increase the sale price of the product, limiting access for patients with lower economic backgrounds.
- Strict government regulations: The stringent regulatory frameworks can hinder accelerated approval in the peptide therapeutics market. This can create delays in the process of production or distribution. The developmental aspects such as new delivery methods and complex formulations of peptides are still unclear, which may put future drug discoveries under strict scrutiny. In addition, such restrictive regulations can refrain companies from investing in R&D of this industry.
Peptide Therapeutics Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.3% |
|
Base Year Market Size (2024) |
USD 46.83 billion |
|
Forecast Year Market Size (2037) |
USD 103.62 billion |
|
Regional Scope |
|
Peptide Therapeutics Segmentation
Application (Cancer, Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Pain, Dermatological Disorders, Neurological Disorders, Renal Disorders)
Metabolic disorders segment is predicted to dominate around 39.3% peptide therapeutics market share by the end of 2037. The increasing prevalence of metabolic diseases such as obesity, type 2 diabetes, and metabolic syndrome have inflated the demand for effective treatments and medications. According to a report published by WHO in November 2024, worldwide around 800 million people are affected with diabetes. The report further states that in 2022, 59% of the total diabetic patients were left untreated. Such reports show the need for introducing more generally available and affordable treatment solutions and therapeutics. This is further escalating the demand in the industry for future innovations and investments.
Type (Generic, Innovative)
In terms of type, the innovative segment is expected to garner significant revenue in the peptide therapeutics market due to the continuous investment in R&D. New compositions introduced till now have proven their efficiency in treating complex and rare diseases through their enhanced targeting capabilities. Many companies are now offering an uninterrupted supply of raw materials and technologies, fueling the process of new drug discovery. For instance, in May 2023, SynCrest launched CRDMO services for pharmaceutical companies and research institutions in developing regions. The one-stop service aims to offer accommodations such as synthesis methods, manufacturing technologies, and raw materials with improved purity for clinical studies and drug development.
Our in-depth analysis of the peptide therapeutics market includes the following segments:
|
Application |
|
|
Type |
|
|
Type of Manufacturers |
|
|
Route of Administration |
|
|
Synthesis Technology |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPeptide Therapeutics Industry - Regional Synopsis
North America Market Analysis
North America industry is poised to hold largest revenue share of 47.2% by 2037. The growth of the region is majorly driven by its well-established biopharmaceutical industry. Growing incidences of a wide range of diseases including cancer, diabetes, cardiovascular conditions, and neurological disorders are encouraging the development of this sector. According to a CDC report published in February 2024, around 129 million U.S. citizens suffer from at least one major chronic disease. The report further states that about 90% of the total health expenditure goes to preventing or treating such chronic diseases. This displays the increasing demand and scope of profit for the future participants of this region.
The significant growth in the U.S. peptide therapeutics market is driven by the efforts in development by the domestic pharmaceutical leaders. The companies are teaming up to push their reach in biotechnology further for more drug discoveries. For instance, in June 2023, Merck & Co. Inc. collaborated with IRBM to develop new peptide candidates for clinical use. The team will utilize novel technologies such as mRNA display platforms, half-life extension strategies, and formulation enhancers in the development process.
Canada is broadening its network of peptide therapeutics market through involvement in deep research and development. The pharmaceutical leaders of this country are taking the initiative to accelerate the progress of innovation. For instance, in January 2022, Fusion Pharmaceuticals collaborated with 48Hour Discovery to develop peptide-based radiopharmaceuticals to treat various solid tumors. The strategic research partnership validates the potential of peptide drug candidates in this field in discovering solutions for unmet medical needs.
APAC Market Statistics
The Asia Pacific peptide therapeutics market is enlarging due to the increasing healthcare needs of this region. The concerning number of cancer and diabetes cases has influenced pharmaceutical and biotechnology-driven companies to engage in R&D. They are focusing on developing effective alternatives for targeted therapeutic actions. Many international companies are expanding their peptide drug pipeline in this region to supply such an inflating consumer base. Countries with well-established healthcare infrastructure are leveraging investment opportunities for local domestic companies. For instance, in September 2024, SK pharmteco invested USD 260 million to build a new small molecule and peptide manufacturing facility in Sejong, South Korea. Such expansion is further enlarging the regional landscape.
India is accelerating its growth in the peptide therapeutics market through its well-developed pharmaceutical industry. Many domestic biopharmaceutical companies are contributing to expanding the country’s peptide drug pipeline to compete with the international leaders. For instance, in September 2024, Biocon partnered with Tabuk Pharmaceuticals to commercialize its GLP -1 products for treating diabetes and obesity in Middle East countries. The Licensing and supply agreement will further help Biocon to expand its portfolio by gaining rights to develop and manufacture its peptide drugs in the region.
China with its large manufacturing force, is augmenting to outstretch the reach of its peptide therapeutics market. The local leaders are leveraging their production of peptide products to supply the increasing global demand. For instance, in January 2024, WuXi AppTec tripled its peptide manufacturing capacity by combining its Changzhou and Taixing plants to feed the surge for therapeutics. The expansion consists of increasing its SPPS volume to 32,000 liters which will utilize the digital operating system to optimize production.
Companies Dominating the Peptide Therapeutics Landscape
- Eli Lilly and Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Novo Nordisk A/S
- GlaxoSmithKline plc.
- Ironwood Pharmaceuticals, Inc.
- Radius Health, Inc.
- Secarna Pharmaceuticals GmbH & Co. KG
- Ipsen Pharma
- WuXi AppTec
- Bristol Myers Squibb
The key players in the industry are focusing on introducing new and more efficient formulations. They are teaming up to leverage each other’s expertise in peptide production to offer innovative therapeutics. For instance, in November 2022, Exelixis collaborated with Cybrexa to acquire CBX-12 to develop topoisomerase inhibitors with less toxicity and improved efficacy. The current dynamics of the peptide drugs market are evolving through the integration of advanced technologies to introduce innovative and more effective formulations. Global leaders are adopting new technologies such as AI and machine learning to enhance drug performance and delivery methods. Such key players include:
In the News
- In May 2024, Secarna collaborated with Orbit Discovery Ltd. to discover and develop peptide-conjugated targeted ASO therapeutics. According to the agreement, Orbit will enhance its expertise and bead-based peptide display engine to identify, screen, and select cyclic peptides to pair with Secarna’s ASO.
- In March 2024, AstraZeneca acquired Amolyt Pharma to expand its metabolism franchise by adding the Phase III investigational therapeutic peptide, eneboparatide. The acquisition will help the company accelerate innovations in the pipeline for rare endocrine diseases, including chronic hypoparathyroidism.
Author Credits: Radhika Pawar
- Report ID: 180
- Published Date: Jan 10, 2025
- Report Format: PDF, PPT
